SCHEMBL5012595

SCHEMBL5012595

COc1ccc(S(=O)(=O)Cl)cc1S(=O)(=O)Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.59
TRPV4 Q9HBA0 1/20 0.53
POLB P06746 2/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.42
HTR6 P50406 1/20 0.42
ALDH1A1 P00352 3/20 0.41
GLA P06280 1/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 2/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31650159 0.89 SMN1; SMN2 (0.77) SMN1; SMN2TRPV4POLBTSHRMAPK1
SCHEMBL4188145 0.89 SMN1; SMN2 (0.77) SMN1; SMN2TRPV4POLBTSHRMAPK1
SCHEMBL11440887 0.87 SMN1; SMN2 (0.54) SMN1; SMN2TRPV4POLBTSHRMAPK1
SCHEMBL10800863 0.87 SMN1; SMN2 (0.54) SMN1; SMN2TRPV4POLBTSHRMAPK1
SCHEMBL4192386 0.84 SMN1; SMN2 (0.51) SMN1; SMN2TRPV4POLBTSHRMAPK1
SCHEMBL66188 0.84 TSHR (0.70) SMN1; SMN2POLBTSHRMAPK1ALDH1A1
SCHEMBL18969789 0.83 TSHR (0.54) SMN1; SMN2TRPV4POLBTSHRMAPK1
SCHEMBL4201928 0.83 SMN1; SMN2 (0.50) SMN1; SMN2TRPV4POLBTSHRMAPK1
SCHEMBL4192390 0.83 SMN1; SMN2 (0.50) SMN1; SMN2TRPV4POLBTSHRMAPK1
SCHEMBL4618678 0.83 HTR6 (0.58) SMN1; SMN2TRPV4POLBTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008129288-A2 DISULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-30 WO disclosed
US-6670474-B2 Such as bis-1,2-(2-(2,3-epoxypropyl)phenoxy)ethane; chemical intermediates for formation of epoxy resins PEWS R GARTH (US) 2003-12-30 US disclosed
US-20020151731-A1 Novel epoxide derivatives of allylarylphenols PEWS R GARTH (US) 2002-10-17 US disclosed
US-4945169-A Novel bis-maleimide compounds containing sulfonate linkages INDSPEC CHEMICAL CORPORATION (US) 1990-07-31 US disclosed
US-4438245-A FOR LIGHT SENSITIVE ELEMENTS FUJI PHOTO FILM CO., LTD. (JP) 1984-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151731-A1 Novel epoxide derivatives of allylarylphenols EPHX2, CBR3, CYP4X1 SMN1; SMN2 4841/4885TRPV4 793/4885POLB 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.